Comparative analysis of macrophage associated vectors for use in genetic vaccine.

Mohammad Feraz Ahsan, Milind M Gore
{"title":"Comparative analysis of macrophage associated vectors for use in genetic vaccine.","authors":"Mohammad Feraz Ahsan,&nbsp;Milind M Gore","doi":"10.1186/1479-0556-9-10","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Antigen presentation by non professional antigen presenting cells (APC) can lead to anergy. In genetic vaccines, targeting the macrophages and APC for efficient antigen presentation might lead to balanced immune response. One such approach is to incorporate APC specific promoter in the vector to be used.</p><p><strong>Methods: </strong>Three promoters known to be active in macrophage were selected and cloned in mammalian expressing vector (pAcGFP1-N1) to reconstruct (pAcGFP-MS), (pAcGFP-EMR) and (pAcGFP-B5I) with macrosialin, EmrI and Beta-5 Integrin promoters respectively. As a positive control (pAcGFP-CMV) was used with CMV promoter and promoterless vector (pAcGFP-NIX) which served as a negative control. GFP gene was used as readout under the control of each of the promoter. The expression of GFP was analyzed on macrophage and non-macrophage cell lines using Flow cytometry and qRT-PCR with TaqMan probe chemistries.</p><p><strong>Results: </strong>All the promoters in question were dominant to macrophage lineage cell lines as observed by fluorescence, Western blot and quantitative RT-PCR. The activity of macrosialin was significantly higher than other macrophage promoters. CMV promoter showed 1.83 times higher activity in macrophage cell lines. The expression of GFP driven by macrosialin promoter after 24 hours was 4.40 times higher in macrophage derived cell lines in comparison with non macrophage cell lines.</p><p><strong>Conclusions: </strong>Based on this study, macrosialin promoter can be utilized for targeting macrophage dominant expression. In vivo study needs to be carried out for its utility as a vaccine candidate.</p>","PeriodicalId":12596,"journal":{"name":"Genetic Vaccines and Therapy","volume":"9 1","pages":"10"},"PeriodicalIF":0.0000,"publicationDate":"2011-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1479-0556-9-10","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genetic Vaccines and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/1479-0556-9-10","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

Background: Antigen presentation by non professional antigen presenting cells (APC) can lead to anergy. In genetic vaccines, targeting the macrophages and APC for efficient antigen presentation might lead to balanced immune response. One such approach is to incorporate APC specific promoter in the vector to be used.

Methods: Three promoters known to be active in macrophage were selected and cloned in mammalian expressing vector (pAcGFP1-N1) to reconstruct (pAcGFP-MS), (pAcGFP-EMR) and (pAcGFP-B5I) with macrosialin, EmrI and Beta-5 Integrin promoters respectively. As a positive control (pAcGFP-CMV) was used with CMV promoter and promoterless vector (pAcGFP-NIX) which served as a negative control. GFP gene was used as readout under the control of each of the promoter. The expression of GFP was analyzed on macrophage and non-macrophage cell lines using Flow cytometry and qRT-PCR with TaqMan probe chemistries.

Results: All the promoters in question were dominant to macrophage lineage cell lines as observed by fluorescence, Western blot and quantitative RT-PCR. The activity of macrosialin was significantly higher than other macrophage promoters. CMV promoter showed 1.83 times higher activity in macrophage cell lines. The expression of GFP driven by macrosialin promoter after 24 hours was 4.40 times higher in macrophage derived cell lines in comparison with non macrophage cell lines.

Conclusions: Based on this study, macrosialin promoter can be utilized for targeting macrophage dominant expression. In vivo study needs to be carried out for its utility as a vaccine candidate.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
巨噬细胞相关载体用于基因疫苗的比较分析。
背景:非专业抗原呈递细胞(APC)抗原呈递可导致能量不足。在基因疫苗中,针对巨噬细胞和APC进行有效抗原呈递可能导致平衡的免疫反应。其中一种方法是将APC特异性启动子合并到要使用的载体中。方法:选择3个已知在巨噬细胞中具有活性的启动子,克隆到哺乳动物表达载体(pAcGFP1-N1)上,分别用macrosialin、EmrI和β -5整合素启动子构建(pAcGFP-MS)、(pAcGFP-EMR)和(pAcGFP-B5I)。阳性对照(pAcGFP-CMV)与CMV启动子和无启动子载体(pAcGFP-NIX)作为阴性对照。在每个启动子的控制下,使用GFP基因作为读数。采用TaqMan探针化学技术,采用流式细胞术和qRT-PCR检测巨噬细胞和非巨噬细胞GFP的表达。结果:通过荧光、Western blot和定量RT-PCR观察,所有启动子在巨噬细胞系细胞株中均为显性。巨噬素的活性明显高于其他巨噬细胞促进剂。巨细胞病毒启动子在巨噬细胞系中活性提高1.83倍。巨噬细胞源性细胞株在巨噬素启动子驱动下,GFP在24 h后的表达量比非巨噬细胞高4.40倍。结论:本研究可以利用macrosialin启动子靶向巨噬细胞显性表达。作为一种候选疫苗,需要进行体内研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Retraction: Structure based sequence analysis & epitope prediction of gp41 HIV1 envelope glycoprotein isolated in Pakistan. DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand? Evaluation of the immune responses induced by four targeted DNA vaccines encoding the juvenile liver fluke antigen, cathepsin B in a mouse model. Targeting wild-type Erythrocyte receptors for Plasmodium falciparum and vivax Merozoites by Zinc Finger Nucleases In- silico: Towards a Genetic Vaccine against Malaria. A brief review on dengue molecular virology, diagnosis, treatment and prevalence in Pakistan.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1